Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer - 12/10/22

Doi : 10.1016/j.cpet.2022.07.001

Cong Hu, MD ^a, Liang Dong, MD ^a, Wei Xue, MD, PhD ^a, Kenneth J. Pienta, MD ^b,^⁎
^a Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Shanghai 200127, China
^b Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA

^∗Corresponding author.

Resumen

Prostate cancer (PCa) is the third most common cancer diagnosed in the world. Since its first identification in 1987 and its first molecular cloning in 1993, prostate-specific membrane antigen (PSMA) has been developed as a theragnostic imaging biomarker and therapeutic agent for PCa. For metastatic castration-resistant PCa, PSMA-based PET imaging can be applied to the monitoring of disease and response assessment with PSMA-based therapeutics. This novel imaging modality is bringing new insights into diagnosis, stratification, and clinical decision-making and treatment.

El texto completo de este artículo está disponible en PDF.

Keywords : Prostate cancer, PET, Prostate-specific membrane antigen, Metastasis-directed therapy